ClinicalTrials.gg
CompletedNCT01952145DUAL™ VUpdated Jan 3, 2019Results posted

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus

A Phase 3 interventional study of insulin degludec/liraglutide and insulin glargine in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 91 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-03.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
557
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.

Enrollment
12th of 70
557 · median 384
Started
2013
with 7 others
Phase 3
49 of 70
2 open now
Registered
38th of 70
by date
Lead sponsor
56 of 70
Novo Nordisk A/S

Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 12th largest by enrollment, is one of 8 that started in 2013, is one of 49 in phase 3, and was the 38th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted globally. The aim of the trial is to compare the efficacy and safety of insulin degludec/liraglutide versus insulin glargine in subjects with type 2 diabetes mellitus.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 557 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: - Type 2 diabetes mellitus - 7.0-10.0% [53-86 mmol/mol] (both inclusive) by central laboratory analysis - Current treatment with insulin glargine for at least 90 days prior to screening - Stable daily dose of insulin glargine between 20 units and 50 units (both inclusive) for at least 56 days prior to screening. Total daily dose should be within the range of 20-50 units, both inclusive, on the day of screening, but individual fluctuations of plus/minus 10 procent within the 56 days prior to screening are acceptable - Stable daily dose of metformin (above or equal to 1500 mg or max tolerated dose) for at least 90 days prior to screening - (BMI) below or equal to 40 kg/m\^2 Exclusion Criteria: - Any use of oral antidiabetic agents (OADs) (except for metformin) within 90 days prior to Visit 1 (screening) - Current use of any drug (except metformin and insulin glargine) or anticipated change inconcomitant medication, which in the investigator's opinion could interfere with the glucose metabolism (e.g. systemic ) - Previous and/or current treatment with any insulin regimen other than basal insulin, e.g. prandial or pre-mixed insulin (short term treatment due to intercurrent illness includinggestational diabetes is allowed at the discretion of the investigator) - Previous and/or current treatment with glucagon-like peptide-1 (GLP-1) receptor agonists (e.g. exenatide, liraglutide) - Impaired liver function, defined as ALAT () above or equal to 2.5 times upper normal range (UNR) - Impaired renal function defined as serum-creatinine above or equal to 133 micromol/L (above or equal to 1.5 mg/dL) for males and above or equal to 125 micromol/L (1.4 mg/dL) for females, or as allowed according to local for metformin - Screening calcitonin above or equal to 50 ng/L - Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) - History of chronic pancreatitis or idiopathic acute pancreatitis

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
557 participants (actual)

Study arms

  • Experimental
    Insulin degludec/liraglutide OD plus metformin

    Drug: insulin degludec/liraglutide

  • Active comparator
    Insulin glargine OD plus metformin

    Drug: insulin glargine

Interventions

  • Druginsulin degludec/liraglutide

    Drug pages: Insulin degludec · Liraglutide

    Insulin degludec/liraglutide is injected subcutaneously s.c. (under the skin) once daily (OD). Dose individually adjusted. Subjects should continue their pre-trial treatment with metformin.

  • Insulin glargine is injected subcutaneously s.c. (under the skin) once daily (OD). Dose individually adjusted. Subjects should continue their pre-trial treatment with metformin.

07

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c (Glycosylated Haemoglobin)

    Change from baseline in HbA1c after 26 weeks of treatment

    Time frame: Week 0, week 26

Secondary outcomes

  1. Change From Baseline in Body Weight

    Change from baseline in body weight after 26 weeks of treatment

    Time frame: Week 0, week 26

  2. Number of Treatment Emergent Confirmed Hypoglycaemic Episodes

    Confirmed hypoglycaemic episodes were defined as either: Severe (i.e., an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions) or an episode biochemically confirmed by a plasma glucose value of \<3.1 mmol/L (56 mg/dL), with or without symptoms consistent with hypoglycaemia.

    Time frame: During 26 weeks of treatment

08

Results

Posted Jan 20, 2017

Participant flow

The trial was conducted at 75 sites in 10 countries as follows: Argentina: 5 sites; Australia: 4 sites; Greece: 6 sites, Hungary: 4 sites; Mexico: 5 sites, Russian Federation: 11 sites; Slovakia: 11 sites, South Africa: 4 sites; Spain: 6 sites, United States: 19 sites.

Participant flow — Overall Study
MilestoneInsulin Degludec/Liraglutide (IDegLira)Insulin Glargine (IGlar)
Started278279
Completed250265
Not completed2814
Withdrew: Protocol violation21
Withdrew: Death01
Withdrew: Adverse event90
Withdrew: Withdrawal criteria1611
Withdrew: Unclassified11

Outcome measures

PrimaryChange From Baseline in HbA1c (Glycosylated Haemoglobin)

Change from baseline in HbA1c after 26 weeks of treatment

Time frame:
Week 0, week 26
Reported as:
Mean · Percentage (%)
Change From Baseline in HbA1c (Glycosylated Haemoglobin)
Percentage (%)Insulin Degludec/Liraglutide (IDegLira)Insulin Glargine (IGlar)
Change From Baseline in HbA1c (Glycosylated Haemoglobin)-1.81 ± 1.08-1.13 ± 0.98
Statistical analysis
  • Insulin Degludec/Liraglutide (IDegLira) vs Insulin Glargine (IGlar) · ANCOVA · p = < 0.001 · Treatment contrast: -0.59 · 95% CI -0.74 to -0.45
SecondaryChange From Baseline in Body Weight

Change from baseline in body weight after 26 weeks of treatment

Time frame:
Week 0, week 26
Reported as:
Mean · Kg
Change From Baseline in Body Weight
KgInsulin Degludec/Liraglutide (IDegLira)Insulin Glargine (IGlar)
Change From Baseline in Body Weight-1.4 ± 3.51.8 ± 3.6
SecondaryNumber of Treatment Emergent Confirmed Hypoglycaemic Episodes

Confirmed hypoglycaemic episodes were defined as either: Severe (i.e., an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions) or an episode biochemically confirmed by a plasma glucose value of \<3.1 mmol/L (56 mg/dL), with or without symptoms consistent with hypoglycaemia.

Time frame:
During 26 weeks of treatment
Reported as:
Number · Number of episodes
Number of Treatment Emergent Confirmed Hypoglycaemic Episodes
Number of episodesInsulin Degludec/Liraglutide (IDegLira)Insulin Glargine (IGlar)
Number of Treatment Emergent Confirmed Hypoglycaemic Episodes289683

Adverse events

Collected over Week 0 to week 27 (26-week treatment period and a follow-up visit 1 week after end of treatment). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Insulin Degludec/Liraglutide (IDegLira)—5/278 (1.8%)52/278 (18.7%)
Insulin Glargine (IGlar)—9/279 (3.2%)22/279 (7.9%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventInsulin Degludec/Liraglutide (IDegLira)Insulin Glargine (IGlar)
CholelithiasisHepatobiliary disorders1/2780/279
Postmenopausal haemorrhageReproductive system and breast disorders1/2780/279
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2780/279
Rectal adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2780/279
Vertebrobasilar insufficiencyNervous system disorders1/2780/279
Acute coronary syndromeCardiac disorders0/2781/279
AppendicitisInfections and infestations0/2781/279
ArrhythmiaCardiac disorders0/2781/279
Auricular perichondritisEar and labyrinth disorders0/2781/279
Biliary colicHepatobiliary disorders0/2781/279
Most frequent other events
Most frequent other events
EventInsulin Degludec/Liraglutide (IDegLira)Insulin Glargine (IGlar)
NauseaGastrointestinal disorders26/2783/279
DiarrhoeaGastrointestinal disorders20/2787/279
VomitingGastrointestinal disorders14/2785/279
HeadacheNervous system disorders11/27814/279

Baseline characteristics

Full analysis set (FAS) was used for baseline measurements. FAS included all randomised subjects.

Age, Continuous
Age, Continuous(Years)Insulin Degludec/Liraglutide (IDegLira)Insulin Glargine (IGlar)Total
Mean58.4 ± 9.859.1 ± 9.358.8 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)Insulin Degludec/Liraglutide (IDegLira)Insulin Glargine (IGlar)Total
Female135142277
Male143137280
Glycated hemoglobin (HbA1c)
Glycated hemoglobin (HbA1c)(Percentage (%))Insulin Degludec/Liraglutide (IDegLira)Insulin Glargine (IGlar)Total
Mean8.4 ± 0.98.2 ± 0.98.3 ± 0.9
Body weight
Body weight(Kg)Insulin Degludec/Liraglutide (IDegLira)Insulin Glargine (IGlar)Total
Mean88.3 ± 17.587.3 ± 15.887.8 ± 16.6
09

Study locations

91 sites
  • Novo Nordisk Investigational Site
    Fresno, California 93720, United States
  • Novo Nordisk Investigational Site
    Los Alamitos, California 90720, United States
  • Novo Nordisk Investigational Site
    Palm Springs, California 92262, United States
  • Novo Nordisk Investigational Site
    San Diego, California 92111, United States
  • Novo Nordisk Investigational Site
    Colorado Springs, Colorado 80906, United States
  • Novo Nordisk Investigational Site
    Colorado Springs, Colorado 80909, United States
  • Novo Nordisk Investigational Site
    Bradenton, Florida 34201, United States
  • Novo Nordisk Investigational Site
    Fort Lauderdale, Florida 33316, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33165, United States
  • Novo Nordisk Investigational Site
    Pembroke Pines, Florida 33027, United States
  • Novo Nordisk Investigational Site
    Tampa, Florida 33603, United States
  • Novo Nordisk Investigational Site
    Gurnee, Illinois 60031, United States
  • Novo Nordisk Investigational Site
    Evansville, Indiana 47725, United States
  • Novo Nordisk Investigational Site
    Michigan City, Indiana 46360, United States
  • Novo Nordisk Investigational Site
    Lexington, Kentucky 40503, United States
  • Novo Nordisk Investigational Site
    Louisville, Kentucky 40213, United States
  • Novo Nordisk Investigational Site
    Slidell, Louisiana 70461-4231, United States
  • Novo Nordisk Investigational Site
    Saint Charles, Missouri 63303, United States
  • Novo Nordisk Investigational Site
    Wilmington, North Carolina 28401, United States
  • Novo Nordisk Investigational Site
    Franklin, Ohio 45005, United States
  • Novo Nordisk Investigational Site
    Oklahoma City, Oklahoma 73103, United States
  • Novo Nordisk Investigational Site
    Oklahoma City, Oklahoma 73104, United States
  • Novo Nordisk Investigational Site
    Altoona, Pennsylvania 16602, United States
  • Novo Nordisk Investigational Site
    Philadelphia, Pennsylvania 19140, United States
  • Novo Nordisk Investigational Site
    Collierville, Tennessee 38017, United States
  • Novo Nordisk Investigational Site
    Kingsport, Tennessee 37660, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75390-9302, United States
  • Novo Nordisk Investigational Site
    San Antonio, Texas 78224, United States
  • Novo Nordisk Investigational Site
    West Jordan, Utah 84088-8871, United States
  • Novo Nordisk Investigational Site
    Renton, Washington 98057, United States
  • Novo Nordisk Investigational Site
    Spokane, Washington 99218, United States
  • Novo Nordisk Investigational Site
    Buenos Aires, B1704ETD, Argentina
  • Novo Nordisk Investigational Site
    Capital Federal, C1056ABJ, Argentina
  • Novo Nordisk Investigational Site
    Corrientes, 3400, Argentina
  • Novo Nordisk Investigational Site
    Salta, 4400, Argentina
  • Novo Nordisk Investigational Site
    Zárate, B2800DGH, Argentina
  • Novo Nordisk Investigational Site
    Blacktown, New South Wales 2148, Australia
  • Novo Nordisk Investigational Site
    Wollongong, New South Wales 2500, Australia
  • Novo Nordisk Investigational Site
    Herston, Queensland 4029, Australia
  • Novo Nordisk Investigational Site
    Ipswich, Queensland 4305, Australia
  • Novo Nordisk Investigational Site
    Robina, Queensland 4226, Australia
  • Novo Nordisk Investigational Site
    East Ringwood, Victoria 3135, Australia
  • Novo Nordisk Investigational Site
    Athens, GR-11527, Greece
  • Novo Nordisk Investigational Site
    Athens, GR-14233, Greece
  • Novo Nordisk Investigational Site
    Ioannina, 45500, Greece
  • Novo Nordisk Investigational Site
    Larissa, GR-41110, Greece
  • Novo Nordisk Investigational Site
    Thessaloniki, GR-54642, Greece
  • Novo Nordisk Investigational Site
    Thessaloniki, GR-56403, Greece
  • Novo Nordisk Investigational Site
    Thessaloniki, GR-57001, Greece
  • Novo Nordisk Investigational Site
    Budapest, H-1134, Hungary
  • Novo Nordisk Investigational Site
    Eger, 3300, Hungary
  • Novo Nordisk Investigational Site
    Győr, 9024, Hungary
  • Novo Nordisk Investigational Site
    Gyula, 5700, Hungary
  • Novo Nordisk Investigational Site
    Miskolc, 3526, Hungary
  • Novo Nordisk Investigational Site
    Pachuca, Hidalgo 42084, Mexico
  • Novo Nordisk Investigational Site
    Cuernavaca, Morelos 62250, Mexico
  • Novo Nordisk Investigational Site
    Mexico City, México, D.F. 03300, Mexico
  • Novo Nordisk Investigational Site
    Durango, 34000, Mexico
  • Novo Nordisk Investigational Site
    Monterrey, 64460, Mexico
  • Novo Nordisk Investigational Site
    Kazan', 420073, Russia
  • Novo Nordisk Investigational Site
    Kirov, 610014, Russia
  • Novo Nordisk Investigational Site
    Moscow, 117036, Russia
  • Novo Nordisk Investigational Site
    Moscow, 123448, Russia
  • Novo Nordisk Investigational Site
    Novosibirsk, 630117, Russia
  • Novo Nordisk Investigational Site
    Saint Petersburg, 194354, Russia
  • Novo Nordisk Investigational Site
    Saint Petersburg, 194358, Russia
  • Novo Nordisk Investigational Site
    Saint Petersburg, 199034, Russia
  • Novo Nordisk Investigational Site
    Tomsk, 634041, Russia
  • Novo Nordisk Investigational Site
    Tomsk, 634050, Russia
  • Novo Nordisk Investigational Site
    Volgograd, 400131, Russia
  • Novo Nordisk Investigational Site
    Vsevolozhsk, 188643, Russia
  • Novo Nordisk Investigational Site
    Bardejov, 08501, Slovakia
  • Novo Nordisk Investigational Site
    Dolný Kubín, 02601, Slovakia
  • Novo Nordisk Investigational Site
    Košice, 040 11, Slovakia
  • Novo Nordisk Investigational Site
    Košice, 04001, Slovakia
  • Novo Nordisk Investigational Site
    Levice, 93401, Slovakia
  • Novo Nordisk Investigational Site
    Ľubochňa, 03491, Slovakia
  • Novo Nordisk Investigational Site
    Poprad, 05801, Slovakia
  • Novo Nordisk Investigational Site
    Považská Bystrica, 01701, Slovakia
  • Novo Nordisk Investigational Site
    Prievidza, 97101, Slovakia
  • Novo Nordisk Investigational Site
    Trnava, 91701, Slovakia
  • Novo Nordisk Investigational Site
    Veľký Meder, 93201, Slovakia
  • Novo Nordisk Investigational Site
    Midrand, Gauteng 1685, South Africa
  • Novo Nordisk Investigational Site
    Durban, KwaZulu-Natal 4450, South Africa
  • Novo Nordisk Investigational Site
    Alberton, 1449, South Africa
  • Novo Nordisk Investigational Site
    Almería, 04001, Spain
  • Novo Nordisk Investigational Site
    Granada, 18012, Spain
  • Novo Nordisk Investigational Site
    Palma de Mallorca, 07014, Spain
  • Novo Nordisk Investigational Site
    Seville, 41003, Spain
  • Novo Nordisk Investigational Site
    Seville, 41010, Spain
  • Novo Nordisk Investigational Site
    Valencia, 46026, Spain
10

References and documents

Publications

  • Lingvay I, Perez Manghi F, Garcia-Hernandez P, Norwood P, Lehmann L, Tarp-Johansen MJ, Buse JB; DUAL V Investigators. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial. JAMA. 2016 Mar 1;315(9):898-907. doi: 10.1001/jama.2016.1252. PubMed 26934259 ↗
  • Hunt B, Mocarski M, Valentine WJ, Langer J. Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA. J Med Econ. 2017 Jul;20(7):663-670. doi: 10.1080/13696998.2017.1301943. Epub 2017 Mar 15. PubMed 28294641 ↗
  • Hunt B, Mocarski M, Valentine WJ, Langer J. Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA. Adv Ther. 2017 Apr;34(4):954-965. doi: 10.1007/s12325-017-0502-2. Epub 2017 Mar 9. PubMed 28281218 ↗
  • Norwood P, Chen R, Jaeckel E, Lingvay I, Jarlov H, Lehmann L, Heller S. Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used. Diabetes Obes Metab. 2017 Nov;19(11):1562-1569. doi: 10.1111/dom.12972. Epub 2017 Jul 10. PubMed 28417535 ↗
  • Lingvay I, Harris S, Jaeckel E, Chandarana K, Ranthe MF, Jodar E. Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial. Diabetes Obes Metab. 2018 Jan;20(1):200-205. doi: 10.1111/dom.13043. Epub 2017 Jul 31. PubMed 28643425 ↗
  • Psota M, Psenkova MB, Racekova N, Ramirez de Arellano A, Vandebrouck T, Hunt B. Cost-effectiveness analysis of IDegLira versus basal-bolus insulin for patients with type 2 diabetes in the Slovak health system. Clinicoecon Outcomes Res. 2017 Dec 12;9:749-762. doi: 10.2147/CEOR.S143127. eCollection 2017. PubMed 29276398 ↗
  • Lingvay I, Handelsman Y, Linjawi S, Vilsboll T, Halladin N, Ranc K, Liebl A. EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES. Endocr Pract. 2019 Feb;25(2):144-155. doi: 10.4158/EP-2018-0284. Epub 2018 Nov 1. PubMed 30383495 ↗
  • Natale P, Green SC, Tunnicliffe DJ, Pellegrino G, Toyama T, Strippoli GF. Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes. Cochrane Database Syst Rev. 2025 Feb 18;2(2):CD015849. doi: 10.1002/14651858.CD015849.pub2. PubMed 39963952 ↗
  • Philis-Tsimikas A, Aroda VR, De Block C, Billings LK, Liebl A, Sivarathinasami R, D'Cruz JM, Lingvay I. Higher Derived Time in Range With IDegLira Versus Insulin Glargine U100 in People With Type 2 Diabetes. J Diabetes Sci Technol. 2024 May;18(3):653-659. doi: 10.1177/19322968221149041. Epub 2023 Jan 29. PubMed 36710452 ↗
  • Meneghini L, Doshi A, Gouet D, Vilsboll T, Begtrup K, Orsy P, Ranthe MF, Lingvay I. Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin. Diabet Med. 2020 Feb;37(2):267-276. doi: 10.1111/dme.14178. Epub 2019 Nov 28. PubMed 31705547 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2013 to primary completion in Nov 2014, 13 months.

Results were first posted in Jan 2017, 2 years 2 months after primary completion. A results delay was requested in Oct 2016.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 13 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2013
First posted
Sep 27, 2013
StartActual
Sep 20, 2013
Primary completionActual
Nov 4, 2014
CompletionActual
Nov 4, 2014
Results delay requested
Oct 4, 2016
Results first posted
Jan 20, 2017
Last update
Jan 3, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01952145
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Sep 27, 2013
Start date
Sep 20, 2013
Primary completion
Nov 4, 2014
Completion
Nov 4, 2014
Results posted
Jan 20, 2017
Last update
Jan 3, 2019

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin degludec · Liraglutide

Start the discussion